 |
|
 |
- December 1, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Platelets in Diabetes: An Important Therapeutic Target"Prof. Karlheinz Peter (biography)
English - 2006-05-07 - 39 minutes
|
 | (23 slides) |
Summary :
In this presentation Prof. Peter talks about the role of platelets in diabetes-induced atherosclerosis and its complications, as well as anti-platelet therapy and associated issues in diabetic patients.
Platelets are now thought to play an important role not only in the end stage of atherosclerosis but in the beginning and middle phases as well. In the context of diabetes, in a recent study reported by Angiolillo and colleagues, diabetic patients were found to have increased platelet activation and a higher number of non-responders to anti-platelet drugs compared to non-diabetic subjects (1). Diabetic patients also seem to benefit more form glycoprotein IIb/IIIa inhibitor therapy (2).
The mechanisms of platelet activation in diabetic patients are not fully understood, and are currently a focus of study by Prof. Peter and colleagues at the Baker Heart Research Institute, with a view to identifying therapeutic targets. Prof. Peter describes the different kinds of anti-platelet agents available and talks about the potential need for monitoring and individual dosing of anti-platelet drugs in diabetic patients.
Copyright © 2006 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation, the participant will be able to discuss:
- The history of anti-platelet therapy
- The role of platelets in different phases of atherosclerosis
- Platelet activation in diabetic patients
- Targets for platelet inhibition
- Response to and benefit of anti-platelet therapy in diabetic patients
Bibliographic references :
1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M,
Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C,
Costa MA, Bass TA, Macaya C.Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel Treatment Diabetes 54:2430-2435, 2005.
2. Marc S. Sabatine, MD; Eugene Braunwald, MD Will Diabetes Save the Platelet Blockers? Circulation. 2001;104:2759.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
